About
CatalYm

Pioneers in neutralizing GDF-15
to overcome cancer therapy resistance

CatalYm has identified GDF-15 as a key cancer therapy resistance mechanism and is developing a safe and efficacious immune therapy for solid tumors. GDF-15, a local immunosuppressant expressed during cellular stress responses, is hijacked by cancer cells to evade immune system attacks. Visugromab, CatalYm’s lead antibody, has demonstrated durable anti-tumor efficacy with long-lasting objective responses in relapsed and refractory metastatic solid tumor patients in combination with anti-PD-1. CatalYm is now advancing into Phase 2b studies to confirm visugromab as a new class of cancer immunotherapy in a broad range of anti-cancer regimens, also in earlier treatment lines.

Our Science

Our Pipeline

Latest News

Leadership Team

+
Chief Executive Officer
+
Chief Financial Officer
+
Chief Technical Officer
+
Chief Medical Officer
+
Chief Scientific Officer
+
SVP of Program Development

Board of Directors

Jon is a Managing Partner at Bioqube Ventures. Previously, he served as Managing Director at Red Tree Venture Capital and was part of the founding team at Medicxi where he was a partner in the London (...)

Read more

Roy Baynes received his MB, BCh (Bachelor of Medicine and Surgery) from the University of Witwatersrand, where he also received an MMed (specialist registration) and completed a PhD exploring mechanisms of human iron metabolism.

After additional clinical training in Johannesburg, and service (...)

Read more

Jasper Bos, PhD is a General Partner at Forbion. He joined the CatalYm board in May 2025.

Jasper, a former Merck executive, joined Forbion as General Partner for the firm’s Growth Fund. Before joining Forbion’s Naarden-based headquarters, Jasper was Senior Vice President and Managing Director (...)

Read more

Colleen Cuffaro is a partner on Canaan’s healthcare investment team.  She serves on the boards of Arrakis Therapeutics, Alphina Therapeutics, RADD Pharmaceuticals and is a board observer at Agomab Therapeutics.  Additionally, Colleen is on the board of Connecticut Innovations and the New England (...)

Read more

Hans van Eenennaam is CEO and founder of IMMIOS and Chief Scientific Officer at Sairopa. Previously, he served as Chief Scientific Officer of AIMM Therapeutics and as Executive Vice President of Antibody Research and Site Head for Aduro Biotech Europe. In 2015, Aduro acquired BioNovion, a company (...)

Read more

Otello founded Omega Funds in 2004 and leads the firm’s investor relations and strategic initiatives. He is a member of the firm’s investment committee and is also heavily involved in a number of Omega’s therapeutic areas of interest, particularly in oncology, rare diseases and inflammatory (...)

Read more

Jonathan is a Partner at Brandon Capital where he heads European operations and serves on the boards of Pheon Therapeutics, Myricx Bio, Astronautx and NRG Therapeutics. Previously, he was Managing Director at Arix Bioscience where he was responsible for numerous early and late-stage biotech investments (...)

Read more

Pascal is an Operating Partner at Jeito Capital, bringing over 40 years of international experience in the biopharmaceutical industry. He has held a range of operational and strategic leadership positions and has served on the boards of several private and public companies.

Throughout his career (...)

Read more

Our Investors

Our mission is supported by a syndicate
of renowned life science investors

WordPress Cookie Notice by Real Cookie Banner